Search
brolucizumab; brolucizumab-dbll (Beovu)
Indications:
- wet age-related macular degeneration [2]
- diabetic macular edema [3]
Dosage:
- 6 mg, intravitreal injection every 4 weeks
- 0.05 mL brolucizumab-dbll 120 mg/mL injection [Beovu]
Clinical significance:
- clinically similar visual outcomes vs aflibercept [3]
Mechanism of action:
- VEGF inhibitor (humanized monoclonal antibody)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
vascular endothelial growth factor (VEGF) inhibitor
pharmaceutical monoclonal antibody
References
- RxNorm
- Wikipedia: Brolucizumab
https://en.wikipedia.org/wiki/Brolucizumab
- Singh RP, Barakat MR, Ip MS et al
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema.
The KINGFISHER Randomized Clinical Trial.
JAMA Ophthalmol. Published online November 16, 2023
PMID: 37971723
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2811933